Clinical Trials Logo
  1. Home
  2. Hypothalamic Obesity
  3. NCT00171613

A Study of Octreotide Depot vs Saline Control in Pediatric Hypothalamic Obesity Patients

Hypothalamic Obesity Clinical Trial

Official title:
A Study of Octreotide Depot vs Saline Control in Pediatric Hypothalamic Obesity Patients

Clinical Trial Summary

The extension protocol is designed to allow those patients randomized to placebo in the core portion of the protocol to receive a 6 month treatment of open label octreotide and allow those patients randomized to octreotide who appeared to benefit from treatment, to continue to receive octreotide.

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00171613
Study type Interventional
Source Novartis
Contact
Status Completed
Phase Phase 4
Start date February 2005
View Details
See also
  Status Clinical Trial Phase
Completed NCT02849743 - Intranasal Oxytocin in Hypothalamic Obesity Phase 2
Recruiting NCT06217848 - The Effect of GLP-1 Agonist in Patients With Hypothalamic Obesity: Prospective, Pilot Study Early Phase 1
Withdrawn NCT05147415 - Study of Tesomet With Open-label Extension in Subjects With Hypothalamic Obesity (HO) Phase 2
Completed NCT00892073 - Hypothalamic Obesity Following Craniopharyngioma Surgery: A Pilot Trial of Combined Metformin and Diazoxide Therapy Phase 2
Not yet recruiting NCT06299891 - Efficacy and Safety of Phentermine/Topiramate in Youth With Hypothalamic Obesity Phase 2
Recruiting NCT06239116 - A Study of RM-718 in Healthy Subjects and in Patients With HO Phase 1
Completed NCT02664441 - Energy Balance & Weight Loss in Craniopharyngioma-related or Other Hypothalamic Tumors in Hypothalamic Obesity Phase 3
Completed NCT04725240 - Open-Label Study of Setmelanotide in Hypothalamic Obesity Phase 2
Completed NCT03673813 - A Personalized Program of Physical Activity and Diet for Hypothalamic Obesity
Not yet recruiting NCT06046443 - A Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesity Phase 2
Withdrawn NCT03708913 - Neuromodulation for Hypothalamic Obesity N/A
Completed NCT01061775 - Effects of Exenatide on Hypothalamic Obesity Phase 1/Phase 2
Completed NCT02860923 - Efficacy and Safety of Exenatide in the Treatment of Hypothalamic Obesity After Craniopharyngioma Therapy Phase 3
Recruiting NCT01783717 - Effects of Exenatide on Obesity and/or Diabetes Mellitus Due to Hypothalamic Damage N/A
Enrolling by invitation NCT05774756 - A Trial of Setmelanotide in Acquired Hypothalamic Obesity Phase 3
Completed NCT05319301 - Identification and Clinical Relevance of an Oxytocin Deficient State (Melatonin Study) N/A